Parkinson's Disease
Conditions
Brief summary
Prospective observational study of Parkinson's disease with repeat clinical assessment and biobanking of blood samples.
Detailed description
To identify genetic and biomarker factors which affect the expression of Parkinson's Disease. Primary objective: To define the severity and rates of progression of clinical features of Parkinson's Disease. Secondary objective: To relate clinical phenomenology of Parkinson's disease to genetic and biomarker changes.
Interventions
None listed
Sponsors
Parkinson's UK
University of Bristol
Cardiff University
University of Glasgow
South Glasgow University Hospitals NHS Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
A. Parkinson's Disease patients Inclusion criteria 1. Diagnosis of Parkinson's disease, based on UK Brain Bank criteria and made within the preceding 3 years ('recent onset cases') or diagnosed at under 50 years ('under 50 years cases') 2. Age ≥18 to \<90years 3. Subject is able and willing to provided informed consent.
Exclusion criteria
1. Patient has severe comorbid illness that would prevent full study participation 2. Patient has features indicating another type of degenerative parkinsonism, e.g. progressive supranuclear palsy 3. Drug-induced parkinsonism (Drug-unmasked PD is allowed) 4. Symmetrical lower body parkinsonism attributable to significant cortical and/or subcortical cerebrovascular disease (patients with 'incidental' small vessel disease on brain imaging are allowed). 5. Negative or normal functional imaging of the presynaptic dopamine system 6. The presence of UK Brain Bank
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants with Parkinson's who have gene mutations and variations | Up to 36 months | Genotyping for leucine rich repeat kinase 2 (LRRK2), Glucocerebrosidase (GBA) (all cases) and Parkin, Phosphatase and tensin homolog-induced putative kinase 1 (PINK1)(onset\<50years) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Categorisation of subtypes of Parkinson's using cluster analysis | At 4 years | Clustering of motor and non-motor features measured using Movement Disorder Society Unified Parkinson's disease rating scale (MDS-UPDRS), Montréal cognitive assessment (MoCA), Non-motor symptom Scale (NMSS), Scale for outcomes in Parkinson's autonomic (SCOPA-AUT), Olfaction testing using University of Pennsylvania Smell Identification Test (UPSIT) or Sniffin' sticks, and Leeds anxiety and depression scale (LADS). This will use sequential factor analysis of the results of the above assessments, followed established methods, firstly exploratory factor analysis and secondly confirmatory factor analysis. Factor scores and other clinically important variables will then be combined to construct a single dataset for carrying out the cluster analysis. Hierarchical clustering will then be applied, and models with between 2 and 5 clusters will be described and compared. |
| Proportion of cases with Parkinson's who have vascular comorbidity and risk factors | At 4 years | Prior history of vascular events, or calculated using Quantification of Risk version 2 (QRISK2) vascular risk score |
Outcome results
None listed